Many PKC modulators are presently at various stages of development in the clinical setting; however, most of these trials have failed to show a significant clinical benefit [10,15,133], which strongly limits the ability to develop cancer treatment strategies by targeting PKC alone. The gene discussed is PRRT2; the disease is cancer.